KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other financing activities (2018 - 2025)

TherapeuticsMD (TXMD) has disclosed Other financing activities for 11 consecutive years, with $23000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Other financing activities fell 79.28% year-over-year to $23000.0, compared with a TTM value of $298000.0 through Mar 2025, up 7.97%, and an annual FY2023 reading of $1.3 million, down 61.74% over the prior year.
  • Other financing activities was $23000.0 for Q1 2025 at TherapeuticsMD, down from $111000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $5.1 million in Q2 2021 and bottomed at -$5.1 million in Q4 2021.
  • Average Other financing activities over 5 years is $429727.3, with a median of $111000.0 recorded in 2024.
  • The sharpest move saw Other financing activities skyrocketed 150.66% in 2022, then plummeted 251.85% in 2023.
  • Year by year, Other financing activities stood at -$5.1 million in 2021, then surged by 150.66% to $2.6 million in 2022, then tumbled by 50.98% to $1.3 million in 2023, then tumbled by 91.27% to $111000.0 in 2024, then tumbled by 79.28% to $23000.0 in 2025.
  • Business Quant data shows Other financing activities for TXMD at $23000.0 in Q1 2025, $111000.0 in Q1 2024, and $1.3 million in Q4 2023.